ERBB2 and neoplasm: For example, a HER2-targeting ADC conjugated with a novel exatecan payload (Ed9, cLogD > 2) demonstrated efficient tumor bystander killing in both in vitro studies and murine xenograft models with heterogeneous HER2 expression [141].